Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Jakub Żołnierek; Paweł Nurzyński; Przemysław Langiewicz; Sylwia Oborska; Anna Waśko-Grabowska; Ewa Kusztal; Beata Obrocka; Cezary Szczylik

eISSN: 1897-4309
ISSN: 1428-2526

Contemporary Oncology/Współczesna Onkologia

Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

7/2008
vol. 12

Send email

Copy url:

abstract:

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Jakub Żołnierek

,

Paweł Nurzyński

,

Przemysław Langiewicz

,

Sylwia Oborska

,

Anna Waśko-Grabowska

,

Ewa Kusztal

,

Beata Obrocka

,

Cezary Szczylik

Współczesna Onkologia (2008) vol. 12; 7 (308–313)

Online publish date: 2008/11/03

View full text Get citation

Background: This single-centre retros-pective analysis of data from three randomized studies and two expanded-access studies compared the effect of interferon (IFN)-alpha, sunitinib, and sorafenib on the occurrence and progression of metastatic bone lesions in patients with renal cell carcinoma (RCC).
Material and methods: In total, 292 patients were included in the analysis; 107 received sunitinib 50 mg/day in 6-week cycles (Schedule 4/2), 147 received sorafenib 800 mg/day, and 38 received placebo or IFN-alpha 9 MU three times per week.
Results: Pre-existing metastatic bone lesions were reported in 82 patients, of which 30 experienced progression. Twenty-three of 210 patients developed new bone lesions during the study. Overall, sunitinib appeared slightly more effective than sorafenib or IFN-alpha at extending mean time to progression of pre-existing bone lesions (p=0.057). Compared with sorafenib, sunitinib significantly decreased formation (p=0.034) and prolonged time to occurrence of new bone lesions (p=0.047).
Conclusions: Further evaluation of the effect of these therapies on bone metastases in RCC is warranted.

keywords:

Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases

Jakub Żołnierek , Paweł Nurzyński , Przemysław Langiewicz , Sylwia Oborska , Anna Waśko-Grabowska , Ewa Kusztal , Beata Obrocka , Cezary Szczylik

renal cell carcinoma, sunitinib malate, sorafenib tosylate, IFN-alpha, metastasis

Jakub Żołnierek

,

Paweł Nurzyński

,

Przemysław Langiewicz

,

Sylwia Oborska

,

Anna Waśko-Grabowska

,

Ewa Kusztal

,

Beata Obrocka

,

Cezary Szczylik